Journal of Bone and Soft Tissue Tumors (JBST) License
Journal of Bone and Soft Tissue Tumors (JBST) by http://jbstjournal.com/ is licensed under https://creativecommons.org/licenses/by-nc-sa/4.0/
Based on a work at http://jbstjournal.com/.
Permissions beyond the scope of this license may be available at editor.jbst@gmail.com
Journal of Bone and Soft Tissue Tumors (JBST) is the official Journal of The Indian Musculo Skeletal Oncology Society
Clear Cell Sarcoma: A Rare Aggressive Tumor with Potential Diagnostic Challenge
Original Article | Volume 6 | Issue 2 | JBST May-August 2020 | Page 9-11 | Adam Goldman, Matthew Doscher, Neil Lancaster, Paul Lamberti. DOI: 10.13107/jbst.2020.v06i02.24
Author: Adam Goldman[1], Matthew Doscher[1], Neil Lancaster[2], Paul Lamberti[1]
[1]Department of Orthopaedics, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, USA,
[2]Department of Orthopaedics, Franciscan Health- Olympia Fields, Illinois, USA.
Address of Correspondence
Dr. Adam Goldman,
Orthopedic Surgery Resident, Franciscan Health Olympia Fields
20201 S. Crawford Ave, Olympia Fields, IL 60461.
E-mail: adamgoldman91@gmail.com
Abstract
Introduction: Synovial sarcomas of the hand are extremely rare, high grade, slow growing, malignant soft-tissue neoplasms. They represent only a fraction of soft-tissue sarcomas, are usually found in the lower extremities around tendon sheaths, bursae, and joint capsules, and carry a significant risk for recurrence and eventual metastasis to the lymph nodes and lungs. There are limited reports of synovial sarcomas of the hand.
Case Report: A 67-year-old male presented with a slow-growing soft-tissue mass of the proximal right long finger over the course of one year. Initial excision was performed, which provided a diagnosis of monophasic synovial cell sarcoma. Subsequently, the patient underwent further staging with an eventual ray resection of the right long finger and an index ray transfer.
Conclusion: There are unique approaches to a patient with a highly malignant neoplasm in the hand. By performing a ray resection and index ray transfer, the patient was spared the potential side effects of radiation therapy and provided a quality functional and cosmetic outcome. The patient returned to work 4 weeks postoperatively. To the best of our knowledge, this treatment has not been used for a synovial sarcoma of the hand.
Keywords: Hand, synovial sarcoma, soft-tissue sarcoma, soft-tissue neoplasms
Reference:
1. Siegel HJ, Sessions W, Casillas MA Jr., Said-Al-Naief N, Lander PH, Lopez-Ben R. Synovial sarcoma: Clinicopathologic features, treatment, and prognosis. Orthopedics 2007;30:1020-7.
2. Rosa AC, Machado MM, Filho LEG, Albertotti F, Sato E, Figueiredo MAJ et al. Sarcoma sinovial fibroso do pe: Relato de caso. Radiol Bras 2002;35:51-4.
3. Michal M, Fanburg-Smith JC, Lasota J, Fetsch JF, Lichy J, Miettinen M. Minute synovial sarcomas of the hands and feet: A clinicopathologic study of 21 tumors less than 1 cm. Am J Surg Pathol 2006;30:721-6.
4. Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, et al. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. J Clin Oncol 2003;21:1602-11.
5. Pradhan A, Cheung YC, Grimer RJ, Peake D, Al-Muderis OA, Thomas JM, et al. Soft-tissue sarcomas of the hand: Oncological outcome and prognostic factors. J Bone Joint Surg Br 2008;90:209-14.
6. Outani H, Hamada K, Oshima K, Joyama S, Naka N, Araki N, et al. Clinical outcomes for patients with synovial sarcoma of the hand. Springerplus 2014;3:649.
7. Sahoo TK, Dhal I, Das SK, Majumdar SK, Parida DK. Synovial sarcoma of palmar aspect of hand and survival: A rare case report. J Clin Diagn Res 2017;11:XD9-11.
8. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008;97:314‐20.
9. Italiano A, Penel N, Robin YM, Bui B, Le Cesne A, Piperno-Neumann S, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: A study of the French sarcoma group. Ann Oncol 2009;20:425-30.
10. Maia DC, Menezes CK, Bastos TC, de Lima Ferreira LC, Francesconi F. Poorly differentiated synovial sarcoma in the wrist: Case report. An Bras Dermatol 2014;89:816-18.
11. Puhaindrain ME, Healy JH, Athanasian EA. Single ray amputations for tumors of the hand. Clin Orthop Relat Res 2010;468:1390-5.
[Full Text HTML] [Full Text PDF] [XML]
Like this:
Fracture Prosthesis in Giant Cell Tumor of Distal Radius: Precautions and Management
Original Article | Volume 6 | Issue 2 | JBST May-August 2020 | Page 5-8 | Mahesh Kulkarni, Sourab Shetty, Monappa Naik, Sandeep Vijayan. DOI: 10.13107/jbst.2020.v06i02.23
Author: Mahesh Kulkarni[1], Sourab Shetty[1], Monappa Naik[1], Sandeep Vijayan[1]
[1]Department of Orthopaedics, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, India.
Address of Correspondence
Dr. Sourab Shetty,
Department of Orthopaedics, Kasturba Medical College, Manipal Academy of Higher Education, Manipal – 576 104, Udupi, Karnataka, India.
E-mail: sourab.shetty.ss@gmail.com
Abstract
Introduction: Distal radius is one of the common locations for giant cell tumor (GCT) in the second to the fourth decade of life. Based on the extent of the tumor, various treatment options are available such as curettage and bone grafting or use of bone cement, various ablation techniques, excision, and vascularized or non-vascularized fibular graft. However, when subchondral bone and articular surface are involved and the patient is not ready for the fibular grafting, one of the methods described is excision and use of custom-made acrylic prosthesis, of which fracture prosthesis is a complication. Here, we are reporting a case who presented with a fractured prosthesis, the way we managed it and the precautions that can be taken while use of the prosthesis.
Case Report: We are presenting a case of a 42-year-old male who came back after 2 years of implantation with a fractured prosthesis, which happened during a routine activity. There was no evidence of recurrence of the tumor. A discussion about the cause, the management done, precautions to be taken while implanting acrylic prosthesis, and a follow-up of the patient for 3 years is also done.
Conclusion: Acrylic can be used as a cost-efficient material for a prosthesis in both primary excision and revisions in distal radius GCT with good functional results if specific precautions are taken preoperatively and intraoperatively.
Keywords: Acrylic prosthesis, broken prosthesis, fractured prosthesis, radius giant cell tumor.
Reference:
1. Renard AJ, Veth RP, Pruszczynski M, Wobbes T, Lemmens JA, van Horn JR. Giant cell tumor of bone: Oncologic and functional results. J Surg Oncol 1994;57:243-51.
2. Ekardt JJ, Grogan TJ. Giant cell tumor of bone. Clin Orthop Relat Res 1986;204:43-48.
3. Jaffe HL, Lichtenstein L, Portis RB. Giant cell tumor of the bone: Its pathological appearance, grading, supposed variant and treatment. Arch Pathol 1940;30:993-1031.
4. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: Risk factors for recurrence. Clin Orthop Relat Res 2011;469:591-9.
5. O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994;76:1827-33.
6. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69:106-14.
7. Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer 1980;46:1641-9.
8. Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001;27:200-2.
9. Briggs TW, Cobb J, McAuliVe T, Pringle J, Kemp H. Giant cell tumours of bone. J Bone Joint Surg 1990;72B:937.
10. Griend RA, Funderburk CH. The treatment of giant-cell tumors of the distal part of the radius. J Bone Joint Surg Am 1993;75A:899-908.
11. Gold AM. Use of a prosthesis for the distal portion of the radius following resection of a recurrent giant-cell tumor. J Bone Joint Surg 1957;39A:1374.
12. Blake SM, Gie GA. Large pelvic giant cell tumor: A Case report and a review of current treatment modalities. J Arthroplasty 2004;19:1050-4.
13. Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: A review of 349 Cases from a single institution. Cancer Treat Rev 2010;36:1-7.
14. McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW. Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res 2005;438:116-22.
15. Saraf S, Goel S. Complications of resection and reconstruction in giant cell tumour of distal end of radius-an analysis. Indian J Orthop 2005;39:206.
16. Chadha M, Arora SS, Singh AP, Gulati D, Singh AP. Autogenous non-vascularized fibula for treatment of giant cell tumor of distal end radius. Arch Orthop Trauma Surg 2010;130:1467-73.
17. Boons HW, Keijser LC, Schreuder BH, Pruszczynski M, Lemmens JA, Veth RP. Oncologic and functional results after treatment of giant cell tumors of bone. Arch Orthop Trauma Surg 2002;122:17-23.
18. Beyli MS, von Fraunhofer JA. An analysis of causes of fracture of acrylic resin dentures. J Prosthet Dent 1981;46:238-41.
19. Beyli MS, von Fraunhofer JA. Repair of fractured acrylic resin. J Prosthet Dent 1980;44:497-503.
20. Vallittu PK, Lassila VP. Effect of metal strengthener’s surface roughness on fracture resistance of acrylic denture base material. J Oral Rehabil 1992;19:385-91.
[Full Text HTML] [Full Text PDF] [XML]
Like this:
Resection and Reconstruction of Calcaneal Tumors – A Review
Original Article | Volume 6 | Issue 2 | JBST May-August 2020 | Page 2-4 | Subbiah Shanmugam, Sujay Susikar, Murali Kannan. DOI: 10.13107/jbst.2020.v06i02.22
Author: Subbiah Shanmugam[1], Sujay Susikar[1], Murali Kannan[1]
[1]Department of Surgical Oncology, Associate Professor, Centre for Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India.
Address of Correspondence
Dr. Sujay Susikar,
Department of Oncology, Centre for Oncology, Government Royapettah Hospital, Chennai, Tamil Nadu, India.
E-mail: sujaysusikar@gmail.com
Abstract
Introduction: Calcaneum is a rare site for Ewing’s sarcoma. The treatment includes neoadjuvant systemic therapy followed by surgical resection and adjuvant systemic therapy. The reconstruction options in this era of limb salvage for bone tumors are not much established in calcaneal tumors in view of limited reporting. Various other reconstruction options available are allograft, iliac crest autograft, and custom-made prosthesis.
Case Report: We have reported a 13-year-old female patient with Ewing’s sarcoma of calcaneum diagnosed by imaging and biopsy. The patient underwent neoadjuvant chemotherapy and then had undergone total calcanectomy with allograft reconstruction. The post-operative outcomes are fair, and the patient is on adjuvant chemotherapy at present.
Conclusion: Biological reconstruction in the form of allograft is a reliable option with regard to the functional outcomes for calcaneal resections.
Keywords: Calcaneum, Ewing sarcoma, total calcanectomy, allograft.
Reference:
1. Sherif PA, Santa A. Ewing’s sarcoma of the calcaneum. Indian J Med Paediatr Oncol 2017;38:542-4.
2. Imanishi J, Choong PF. Three-dimensional printed calcaneal prosthesis following total calcanectomy. Int J Surg Case Rep 2015;10:83-7.
3. Ottolenghi CE, Petracchi LJ. Chondromyxosarcoma of the calcaneus; report of a case of total replacement of involved bone with a homogenous refrigerated calcaneus. J Bone Joint Surg 1953;35:211-4.
4. Scoccianti G, Campanacci DA, Innocenti M, Beltrami G, Capanna R. Total calcanectomy and reconstruction with vascularized iliac bone graft for osteoblastoma: A report of two cases. Foot Ankle Int 2009;30:716-20.
5. Kurvin LA, Volkering C, Kessler SB. Calcaneus replacement after total calcanectomy via vascularized pelvis bone. Foot Ankle Surg 2008;14:221-4.
6. Anacak Y, Sabah D, Demirci S, Kamer S. Intraoperative extracorporeal irradiation and re-implantation of involved bone for the treatment of musculoskeletal tumors. J Exp Clin Cancer Res 2007;26:571.
7. Li J, Guo Z, Pei GX, Wang Z, Chen GJ, Wu ZG. Limb salvage surgery for calcaneal malignancy. J Surg Oncol 2010;102:48-53.
8. Brenner P, Zwipp H, Rammelt S. Vascularized double barrel ribs combined with free serrate us anterior muscle transfer for homologous restoration of the hind foot after calcanectomy. J Trauma Acute Care Surg 2000;49:331-5.
9. Elsalanty ME, Genecov DG. Bone grafts in craniofacial surgery. Craniomaxillofac Trauma Reconstr 2009;2:125-34.
10. Chou LB, Malawer MM. Osteosarcoma of the calcaneus treated with prosthetic replacement with twelve years of follow up: A case report. Foot Ankle Int 2007;28:841-4.
[Full Text HTML] [Full Text PDF] [XML]
Like this:
Aneurysmal Bone Cyst – Review
Original Article | Volume 6 | Issue 1 | JBST Jan-April 2020 | Page 17-20| DOI: 10.13107/jbst.2020.v06i01.009
Author: Nitin Shetty[1], Prateek Hegde[2], Hemant Singh[3], Ashish Gulia[4]
[1]Department of Radio-Diagnosis, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
[2]Department of Surgical Oncology, Tata Memorial Centre, HBNI, Mumbai, India.
Address of Correspondence
Dr. Ashish Gulia
Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai – 400 012, India.
E- mail: aashishgulia@gmail.com
Abstract
Background: Aneurysmal bone cyst (ABC) is a rare, benign, expansile lesion that produces blood-filled cavities inside the bone. The term, ‘Aneurysmal bone cyst’ was first time used by Jaffe and Lichtenstein in 1942 [1]. The name is a misnomer, as they are neither aneurysmal nor are, they truly cystic, as these lesions do not have an endothelial lined cyst wall. ABC is a disease of childhood or young adulthood with a median age of 13 years, with an incidence of 0.14 per 105 individuals with slight female preponderance [2].
Pathophysiology: ABC usually present as a solitary lesion either as a primary neoplasm (translocation driven) or a secondary lesion arising adjacent to previous bony lesions like giant cell tumours (GCT), osteoblastomas, chondroblastomas [3]. Few authors have proposed post traumatic hypothesis whereas others feel it could due to an hemodynamic disturbance especially venous impedance.
Primary ABCs: Primary ABC is one where it occurs in a bone without any previously known lesion. But now there has been identification of TRE17 also known as USP6 (ubiquitin-specific protease 6) gene on chromosome 17p13.Pathogenesis of some primary ABC involves transcriptional up-regulation of USP6 when there is the chromosomal translocation t(16;17)(q22;p13) which fuses the promoter region of the osteoblast cadherin 11 gene (CDH11) on chromosome 16q22 to the entire coding sequence of the ubiquitin protease USP6 gene on chromosome 17p13 [4].
Secondary ABCs: Approximately one third of the ABCs appear secondary to other pre-existing bone tumours, most commonly from GCT, which accounts for 19-39% of these cases [5]. Other common precursor lesions are chondroblastomas, chondromyxoid fibroma, fibrous dysplasia, osteoblastomas, haemangioendothelioma, angioma, fibroxanthoma (nonossifying fibroma), solitary bone cyst, fibrous histiocytoma, eosinophilic granuloma, radiation osteitis, osteosarcoma, trauma (including fracture), fibrosarcoma and even metastatic carcinoma [3, 5].
ABCs have been likened to a “blood-filled sponge”, composed of blood-filled, anastomosing, cavernomatous spaces, separated by a cyst like wall composed of fibroblasts, myofibroblasts, osteoclast like giant cells, osteoid and woven bone.
In approximately one third of cases, a characteristic reticulated lacy chondroid like material, described as a calcified matrix with a chondroid aura, is seen [6]. These are called as “solid aneurysmal bone cyst”. The term “solid aneurysmal bone cyst,” was coined by Sanerkin et al. in 1983 [7].
References
1. Jaffe HL, Lichtenstein L. Solitary Unicameral Bone Cyst: with emphasis on the roentgen picture, the pathologic appearance and the pathogenesis. Arch Surg. 1942;44(6):1004–1025.
2. Leithner A, Windhager R, Lang S, Haas O, Kainberger F, Kotz R. Aneurysmal bone cyst. A population based epidemiologic study and literature review. Clin Orthop 1999; 363:176–179.
3. Bonakdarpour A, Levy WM, Aegerter E. Primary and secondary aneurysmal bone cyst: A radiological study of 75 cases. Radiology. 1978;126(1):75–83.
4. Oliveira AM, Hsi BL, Weremowicz S, Rosenberg AE, Dal Cin P, Joseph N, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 2004;64:1920–1923.
5. Kransdorf M J and Sweet D E.Aneurysmal bone cyst: concept, controversy, clinical presentation, and imaging. American Journal of Roentgenology. 1995;164:573-580.
6. Mirra JM. Bonetumors: clinical, radiological and pathologic correlations. Philadelphia: Lea & Fefiger; 1989:1233–1334.
7. Sanerkin NG, Mott MG, Roylance J. An unusual intraosseous lesion with fibroblastic, osteoblastic, aneurysmal and fibromyxoid elements: “solid” variant of aneurysmal bone cyst. Cancer. 1983;51:2278 –2286.
8. Capanna R, Bettelli G, Biagini R, Ruggieri P, Bertoni F, Campanacci M. Aneurysmal cysts of long bones. Ital J Orthop Traumatol. 1985;11:409–417.
9. Dabska M, Buraczewski J. Aneurysmal bone cyst: Pathology, clinical course and radiologic appearances. Cancer. 1969;23(2):371-389.
10. Mahnken AH, Nolte-Ernsting CC, Wildberger JE, Heussen N, Adam G, Wirtz DC, et al. Aneurysmal bone cyst: Value of MR imaging and conventional radiography. Eur Radiol. 2003;13(5):1118-1124.
11. Rapp TB, Ward JP, Alaia MJ. Aneurysmal bone cyst. J Am Acad Orthop Surg. 2012;20(4):233–241.
12. Kumar V, Abbas AK, Aster JC. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2015.
13. Murphey MD, wan Jaovisidha S, Temple HT, Gannon FH, Jelinek JS, Malawer MM. Telangiectatic osteosarcoma: radiologic-pathologic comparison. Radiology.2003;229(2):545–553.
14. Wallace MT, Henshaw RM. Results of cement versus bone graft reconstruction after intralesional curettage of bone tumors in the skeletally immature patient. J Pediatr Orthop. 2014;34(1):92–100.
15. Reddy KIA, Sinnaeve F, Gaston CL, Grimer RJ, Carter SR.Aneurysmal bone cysts: do simple treatments work? Clin OrthopRelat Res. 2014;472(6):1901–1910.
16. Steffner RJ, Liao C, Stacy G, Atanda A, Attar S, Avedian R, et al. Factors associated with recurrence of primary aneurysmal bone cysts: is argon beam coagulation an effective adjuvant treatment? J Bone Joint Surg Am. 2011;93(21):1221–1229.
17. Park HY, Yang SK, Sheppard WL, Hegde V, Zoller SD, Nelson SD, et al. Current management of aneurysmal bone cysts. Curr Rev Musculoskelet Med. 2016;9(4):435-444.
18. Vergel De Dios AM, Bond JR, Shives TC, McLeod RA, Unni KK. Aneurysmal bonecyst. A clinicopathologic study of 238 cases. Cancer. 1992;69:2921–2931.
19. Flont P, Kolacinska-Flont M, Niedzielski K. A comparison of cyst wall curettage and en bloc excision in the treatment of aneurysmal bone cysts. World J Surg Oncol.2013;11:109.
20. Elsayad K, Kriz J, Seegenschmiedt H, Imhoff D, Heyd R, Eich HT, et al.Radiotherapy for aneurysmal bone cysts: a rare indication. Strahlenther Onkol.2017;193(4):332-340.
21. Batisse F, Schmitt A, Vendeuvre T, Herbreteau D, Bonnard C. Aneurysmal bone cyst: A 19-case series managed by percutaneous sclerotherapy. Orthop Traumatol Surg Res.2016;102(2):213-216.
22. Varshney MK, Rastogi S, KhanSA, Trikha V. Is sclerotherapy better than intralesional excision for treating aneurysmal bone cysts? Clin Orthop Relat Res. 2010;468(6):1649-1659.
23. Falappa P, Fassari FM, Fanelli A, Genovese E, Ascani E, Crostelli M, et al. Aneurysmal bone cysts: treatment with direct percutaneous Ethibloc injection: long-term results. Cardiovasc Intervent Radiol.2002;25(4):282–290.
24. Rastogi S, Varshney MK, Trikha V, Khan SA, Choudhury B, Safaya R. Treatment of aneurysmal bone cysts with percutaneous sclerotherapy using polidocanol. A review of 72 cases with long-term follow-up.J Bone Joint Surg Br. 2006;88(9):1212–1216.
25. Puri A, Hegde P, Gulia A, Mishil P. (in press). Primary aneurysmal bone cysts – Is percutaneous sclerosant therapy effective? The Bone & Joint Journal.
26. Gupta P, Gamanagatti S. Preoperative transarterial Embolisation in bone tumors. World J Radiol.2012;4(5):186-192.
27. Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J.2013;22(6):1417–1422.
28. Brastianos P, Gokaslan Z, McCarthy EF. Aneurysmal bone cysts of the sacrum: a report of ten cases and review of the literature. Iowa Orthop J.2009;29:74–78.
29. Papagelopoulos PJ, Choudhury SN, Frassica FJ, Bond JR, Unni KK, Sim FH. Treatment of aneurysmal bone cysts of the pelvis and sacrum. J Bone Joint Surg Am.2001;83(11):1674–1681.
30. Terzi S, Gasbarrini A, Fuiano M, Barbanti Brodano G, Ghermandi R, Bandiera S, et al. Efficacy and safety of selective arterial embolization in the treatment of aneurysmal bone cyst of the mobile spine: A retrospective observational study. Spine (Phila Pa 1976).2017;42(15):1130-1138.
31. Rossi G, Rimondi E, Batalena T, Gerardi A, Alberghini M, Staals EL,et al. Selective arterial embolization of 36 aneurysmal bone cysts of the skeleton with N-2-butyl cyanoacrylate. Skeletal Radiol.2010;39(2):161–167.
32. Amendola L, Simonetti L, Simoes CE, Bandiera S, De Iure F, Boriani S. Aneurysmal bone cyst of the mobile spine: the therapeutic role of embolization. Eur Spine J. 2013; 22(3):533-541.
33. Donati D, Frisoni T, Dozza B, DeGroot H, Albisinni U, Giannini S. Advance in the treatment of aneurysmal bone cyst of the sacrum. Skeletal Radiol.2011;40(11):1461-1466.
34. Elsayad K, Kriz J, Seegenschmiedt H, Imhoff D, Heyd R, Eich HT, et al.Radiotherapy for aneurysmal bone cysts: a rare indication. Strahlenther Onkol.2017;193(4):332-340.
35. Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis. 1997;17(6):312–322.
36. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treat Rev.2002;28(6):305–319.
37. Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Sasaki T, Hatano H, et al. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors. PLoS One.2016;11(5):e0154680.
[Full Text HTML] [Full Text PDF] [XML]
Like this:
Editorial IMSOS Issue January – April 2020
Original Article | Volume 6 | Issue 1 | JBST January-April 2020 | Page 21 | DOI: 10.13107/jbst.2020.v06i01.010
Author: Dr. Yogesh Panchwagh[1] , Dr. Ashish Gulia[2] & Dr. Ashok Shyam[3, 4]
1. Orthopaedic Oncology Clinic, Pune, India,
2. Orthopedic Oncology Services, Department of Surgical Oncology,
Tata Memorial Hospital, Mumbai,
3. Indian Orthopaedic Research Group, Thane, India,
4. Sancheti Institute for Orthopaedics &Rehabilitation, Pune, India.
Address of Correspondence:
Dr. Yogesh Panchwagh.
Orthopaedic Oncology Clinic, 101, Vasant plot 29, Bharat Kunj
Society -2, Erandwana, Pune – 38, India.
Email: drpanchwagh@gmail.com
We are pleased to bring you the IMSOS issue for 2020. JBST is the official publication of the Indian musculoskeletal oncology society (IMSOS). This is the second consecutive year that we are publishing a special IMSOS issue, which typically coincides with the IMSOS annual conference in early March.
Since the last year, JBST editorial board has 2 IMSOS life members selected as IMSOS representatives. Dr. Akshay Tiwari and Dr. Dominic Putthoor are the current IMSOS representatives on the JBST editorial board. Both have a vast experience of treating bone and soft tissue tumors and bring along considerable credibility to the work published in the issue.
IMSOS annual conference this year is being held at Bengaluru. The organising secretary Dr. Suman Byregowda and his team have put up an exceptional scientific program. The current IMSOS issue being released online to coincide with the annual conference promises to add to the academic value that IMSOS had aimed at. The conference is being held on the background of the Covid 19 scare that is looking to grip India. Hopefully the great academic content, warm hospitality and gracious hosts will not let the scare dampen the fervor and camaraderie.
JBST wishes IMSOS 2020 the very best.
[Full Text HTML] [Full Text PDF] [XML]
Like this:
Facilitating Timely Access to Highly Specialized Surgery for Children with Extremity Bone and Soft-Tissue Sarcomas in North and Central India
Original Article | Volume 6 | Issue 1 | JBST January-April 2020 | Page 2-4 | DOI: 10.13107/jbst.2020.v06i01.005
Author: Rashmi Kumari [1], Akshay Tiwari [2], Ishita Maji [1], Haresh Gupta [1], Poonam Bagai [1], Mohini
Daljeet Singh [3], Ramandeep Singh Arora [1]
1. Quality Care, Research and Impact Division, Cankids…Kidscan, New Delhi, India,
2. Max Institute of Cancer Care, , Max Super Speciality Hospital, Saket, Delhi, India,
3. Founder CEO, Max India Foundation, Delhi, India.
Address of Correspondence
Dr. Ramandeep Singh Arora,
Department of Musculoskeletal Oncology, Max Institute of Cancer Care, Max Super
Speciality Hospital, Saket, New Delhi – 110 017, India.
E-mail: childhoodcancer@gmail.com
Abstract
Background: Optimal management of bone and soft-tissue sarcomas (BSTSs) of the extremity in low- and middle-income countries like India remains a challenge due to the paucity of surgical expertise and other resource limitations. In this study, we aimed to develop a multiple stakeholder model where children with extremity BSTS in North and Central India can access specialized surgery without experiencing cost and delays.
Materials and Methods: The model brought together four stakeholders and developed a pathway of identifying eligible patients, facilitating timely referral, providing specialized surgery, and sharing the cost. Services were offered for 1 year (2018–2019) under this model.
Results: Sixteen non-metastatic patients (69% osteosarcoma, 18% soft-tissue sarcoma, and 13% Ewing sarcoma) from five hospitals received specialized extremity BSTS surgery under this model. About 69% had limb salvage surgeries, 19% rotationplasty, and 12% amputation. Surgery was done at a median interval of 16.9 weeks (range 7.3–33.6 weeks) from the date of diagnosis. None of the patients abandoned treatment. The total cost for the facilitation of the surgery, supportive care and social support for the entire cohort was INR 38.7 lakh (USD 54,180) with
an average of INR 2.8 lakh per patient (USD 3920). The patient had to bear no cost toward the surgery.
Conclusions: In this study, we developed a model systematically bringing together four stakeholders and identifying eligible patients, facilitating timely referral, providing specialized surgery at zero cost to the patient, and ensuring completion of treatment and follow-up. Our next goal is to increase the capacity of this model by amplifying its scope and replicating it in other parts of India.
Keywords: Child, Health services accessibility, India, Sarcoma.
References
1. AroraRS. Epidemiology of cancers in children. In: GuptaP, MenonPS, RamjiA, LodhaR, editors. PG Textbook of Pediatric. 2015. p. 2416-20.
2. AroraRS, AlstonRD, EdenTO, GeraciM, BirchJM. The contrasting ageincidence patterns of bone tumours in teenagers and young adults: Implications for aetiology.Int J Cancer2012;131:1678-85.
3. McDowellHP. Update on childhood rhabdomyosarcoma.Arch Dis Child2003;88:354-7.
4. SmithMA, SeibelNL, AltekruseSF, RiesLA, MelbertDL, O’LearyM, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century.J Clin Oncol2010;28:2625-34.
5. SiddiquiYS, SherwaniMK, KhanAQ, ZahidM, AbbasM, AsifN. Neglected orthopedic oncology-causes, epidemiology and challenges for management in developing countries.Indian J Cancer2015;52:325-9.
6. HasanO, ZubairiA, NawazZ, UmerM. Establishing musculoskeletal oncology service in resource constrained country: Challenges and solutions.Int J Surg Oncol (N Y)2017;2:e50.
7. GoodladJR, FletcherCD, SmithMA. Surgical resection of primary softtissue sarcoma. Incidence of residual tumour in 95 patients needing reexcision after local resection.J Bone Joint Surg Br1996;78:658-61.
8. FriedrichP, OrtizR, StraitK, FuentesS, GamboaY, ArambúI, et al. Pediatric sarcoma in Central America: Outcomes, challenges, and plans for improvement.Cancer2013;119:871-9.
9. FriedrichP, OrtizR, FuentesS, GamboaY, AhChu-Sanchez MS, ArambúIC, et al. Barriers to effective treatment of pediatric solid tumors in middle-income countries: Can we make sense of the spectrum of nonbiologic factors that influence outcomes?Cancer2014;120:112-25.
10. PapyanR, TamamyanG, DanielyanS, TananyanA, MuradyanA, SaabR. Identifying barriers to treatment of childhood rhabdomyosarcoma in resource-limited settings: A literature review.Pediatr Blood Cancer 2019;66:e27708. 11. HowardSC, PedrosaM, LinsM, PedrosaA, PuiCH, RibeiroRC, et al. Establishment of a pediatric oncology program and outcomes of childhood a c u t e l y m p h o b l a s t i c l e u k e m i a i n a r e s o u r c e – p o o r area.JAMA2004;291:2471-5.
12. MostertS, SitaresmiMN, GundyCM, JanesV, Sutaryo, VeermanAJ. Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia.Arch Dis Child2010;95:20-5.
13. IsraelsT, PaintsilV, NyirendaD, KouyaF, MbahAfungchwi G, HesselingP, et al. Improved outcome at end of treatment in the c o l l a b o r a t i v e w i l m s t u m o u r A f r i c a p r o j e c t . P e d i a t r B l o o d Cancer2018;65:e26945.
[Full Text HTML] [Full Text PDF] [XML]
Like this: